CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this protocol is to investigate the efficacy of the combination of CB-839 with
Niraparib in platinum resistant BRCA wild-type ovarian cancer patients. The primary and
secondary objectives are to determine the maximum tolerated dose of CB-839 in combination
with Niraparib and to determine the response rate and percentage of participants who remain
progression free at 6 months.